La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Delcath Systems a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Delcath Systems..

Delcath Systems (NASDAQ:DCTH) Azioni, Catena delle Opzioni

DELCATH SYSTEMS INC

Delcath Systems

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Delcath Systems Inc

<h3>Gainers</h3>
<ul>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares rose 39.1% to $35.96 during Thursday's regular session. The company's market cap stands at $2.4 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 38.08% to $6.54. The company's market cap stands at $355.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock increased by 32.83% to $15.6. The company's market cap stands at $276.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) stock increased by 24.11% to $14.41. The market value of their outstanding shares is at $481.3 million. As per the press release, Q1 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock moved upwards by 22.84% to $2.85. The market value of their outstanding shares is at $107.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock increased by 21.64% to $6.88. The company's market cap stands at $343.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 74.5% to $0.12 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 69.32% to $0.16. The company's market cap stands at $20.5 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock decreased by 64.04% to $0.11. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 43.31% to $0.23. The market value of their outstanding shares is at $11.8 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) stock fell 29.1% to $1.17. The market value of their outstanding shares is at $25.3 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares fell 28.83% to $3.44. The market value of their outstanding shares is at $123.9 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADVB

AXDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CYRX

DCTH

GNLX

NCNA

QDEL

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Delcath Systems shares are trading higher after the company reported better-than-expected Q1 financial results.

Earnings

Earnings Beats

News

Delcath Systems Q1 EPS $0.03 Beats $0.01 Estimate, Sales $19.80M Beat $16.83M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DIOD

DKNG

Earnings Scheduled For May 8, 2025

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Monday.
Shares of Eagle Financial Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) fell sharply in today's pre-market trading after the company released financial <a href="https://www.benzinga.com/quote/efsi">results for the first quarter</a>.
Eagle Financial Services reported quarterly earnings of 62 cents per share, down from 72 cents per share in the year-ago period.
Eagle Financial Services shares dipped 5.8% to $30.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) shares dipped 10.7% to $12.01 in pre-market trading. Truist Securities analyst Lucas Servera, on April 24, maintained RXO with a Buy and lowered the price target from $24 to $19.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) declined 9.8% to $12.01 in today's pre-market trading. ODP will announce first quarter financial results before the opening bell on Wednesday, May 7.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) shares fell 8.3% to $7.03 in pre-market trading.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) tumbled 6.8% to $6.81 in pre-market trading.</li>
<li>Magnera Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) dipped 6.8% to $13.41 in pre-market trading. Magnera is expected to report second quarter results on May 7.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) fell 6.4% to $9.13 in pre-market trading.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 2.8% to $13.35 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) slipped 2.2% to $11.85 in pre-market trading. Delcath Systems will host a conference call on May 8 to discuss results for its first quarter.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.5% to $109.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ANNA

BLCO

EFSI

HLMN

MAGN

NVDA

OMER

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO&#x2122; in combination with standard of care (SOC) for liver-dominant metastatic breast cancer (mBC). With the FDA's review complete, Delcath is now cleared to initiate patient enrollment in the U.S.
The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with liver-dominant HER2-negative mBC following the failure of previous treatments. The SOC options will be the physician's choice of eribulin, vinorelbine or capecitabine. Approximately 90 patients will be enrolled in this randomized, controlled trial. The study will take place at more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the fourth quarter of 2025. The trial's primary endpoint, hepatic progression-free survival, is anticipated to be announced by the end of 2028, while results for overall survival, a secondary endpoint, are expected in 2029.
Company management estimates that approximately 7,000 patients annually in the United States are affected by HER2-negative metastatic breast cancer with liver metastases and are candidates for third line treatment. This population includes patients with a significant burden of liver metastases, which are likely to be the primary cause of mortality. By focusing on this demographic, Delcath intends to offer a novel therapeutic option to those patients with limited treatment alternatives.
"This randomized Phase 2 trial marks an important milestone as we expand the clinical investigation of HEPZATO into patients with liver-dominant metastatic breast cancer," said Gerard Michel, Chief Executive Officer of Delcath Systems, Inc. "We are excited to bring new hope to patient populations in indications beyond metastatic uveal melanoma and to further demonstrate the potential of HEPZATO to address unmet needs in oncology. This study underscores our commitment to broadening the applications of HEPZATO and the underlying hepatic delivery system, positioning us as a platform technology that can offer directed treatment options for a variety of liver-dominant cancers."

Biotech

General

Delcath Systems Receives FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Liver-Dominant Metastatic Breast Cancer

Delcath Systems Reveals Publication Of Comparative Analysis From Randomized Segment Of FOCUS Study In Metastatic Uveal Melanoma

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and raises the price target from $22 to $24.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $24

Delcath Systems shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.02) by 450 percent. This is a 77.08 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $15.10 million which beat the analyst consensus estimate of $13.78 million by 9.58 percent. This is a 2.70K percent increase over sales of $539.00 thousand the same period last year.

Delcath Systems Q4 2024 GAAP EPS $(0.11) Misses $(0.02) Estimate, Sales $15.10M Beat $13.78M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $227.93 million. 
• KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $28.12 million. 
• Dingdong (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $793.81 million. 
• Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $40.15 million. 
• Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $38.34 million. 
• ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) is likely to report earnings for its fourth quarter. 
• Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is expected to report quarterly loss at $0.02 per share on revenue of $100.41 million. 
• VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is likely to report quarterly loss at $0.04 per share on revenue of $8.21 million. 
• Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $60.00 million. 
• Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $352.00 million. 
• Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) is projected to report quarterly loss at $1.07 per share on revenue of $26.04 million. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) is likely to report earnings for its third quarter. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $401.10 million. 
• Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $102.27 million. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is estimated to report quarterly earnings at $1.91 per share on revenue of $7.84 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is likely to report quarterly earnings at $3.76 per share on revenue of $3.29 billion. 
• Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) is expected to report quarterly earnings at $1.09 per share on revenue of $34.87 billion. 
• Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) is projected to report earnings for its fourth quarter. 
• JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $45.16 billion. 
• Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $12.42 million. 
• Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $836.96 million. 
• GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.29 billion. 
• Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) is expected to report quarterly loss at $0.60 per share on revenue of $300.28 million. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is expected to report quarterly loss at $0.73 per share on revenue of $3.62 million. 
• Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $370.82 million. 
• ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is likely to report quarterly loss at $0.23 per share on revenue of $498.50 million. 
• Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $1.01 billion. 
• Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) is projected to report earnings for its fourth quarter. 
• Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is projected to report earnings for its fourth quarter. 
• BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $2.95 billion. 
• America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $273.39 million. 
• BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) is projected to report quarterly loss at $0.26 per share on revenue of $34.23 million. 
• Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $463.80 million. 
• Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $98.75 million. 
• Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) is expected to report quarterly loss at $0.15 per share on revenue of $634.04 million. 
• Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $8.90 billion. 
• Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $282.20 million. 
• Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $203.10 million. 
• TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $280.86 million. 
• BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $5.30 billion. 
<h3>Companies Reporting After The Bell</h3>
• Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $335.35 million. 
• Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $6.48 million. 
• DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $431.00 million. 
• Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) is projected to report earnings for its fourth quarter. 
• Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $2.37 million. 
• Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) is expected to report earnings for its fourth quarter. 
• Silvercrest Asset Mgmt Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAMG#NASDAQ">SAMG</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $31.97 million. 
• Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) is projected to report quarterly loss at $0.02 per share on revenue of $31.80 million. 
• Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) is likely to report earnings for its fourth quarter. 
• ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $717.27 million. 
• Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) is projected to report quarterly loss at $0.20 per share on revenue of $700 thousand. 
• Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is likely to report quarterly loss at $0.02 per share on revenue of $12.01 million. 
• GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is likely to report quarterly loss at $0.03 per share on revenue of $49.77 million. 
• CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $13.53 million. 
• Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) is estimated to report earnings for its fourth quarter. 
• National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $83.72 million. 
• Fidus Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDUS#NASDAQ">FDUS</a>) is estimated to report quarterly earnings at $0.52 per share on revenue of $36.66 million. 
• Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is estimated to report quarterly loss at $1.61 per share on revenue of $5.00 million. 
• IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is expected to report earnings for its second quarter. 
• Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $119.46 million. 
• Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $45.92 million. 
• Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is expected to report quarterly loss at $0.13 per share on revenue of $254 thousand. 
• Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $69.03 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $285.83 million. 
• Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) is likely to report quarterly loss at $0.25 per share on revenue of $6.40 million. 
• MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $78.53 million. 
• Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $30.82 million. 
• BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) is projected to report quarterly loss at $0.05 per share on revenue of $54.17 million. 
• Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $164.62 million. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is projected to report quarterly loss at $0.16 per share on revenue of $78.00 million. 
• AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $91.78 million. 
• Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $272.74 million. 
• Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is expected to report quarterly loss at $0.02 per share on revenue of $37.96 million. 
• a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) is projected to report quarterly loss at $0.23 per share on revenue of $154.49 million. 
• American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $56.78 million. 
• Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $285.79 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $3.95 million. 
• American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $161.78 million. 
• El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $115.83 million. 
• Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) is likely to report quarterly loss at $0.14 per share on revenue of $121.36 million. 
• Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $115.23 million. 
• Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $221.13 million. 
• Granite Ridge Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRNT#NYSE">GRNT</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $104.93 million. 
• Invesco Dorsey Wright Industrials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRN#NASDAQ">PRN</a>) is likely to report quarterly loss at $0.47 per share on revenue of $5.92 million. 
• Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) is expected to report quarterly loss at $0.34 per share on revenue of $5.92 million. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $4.07 billion. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $7.82 billion. 
• HASHICORP INC CL A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $175.71 million. 
• ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $7.38 million. 
• Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $57.62 million. 
• Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.19 per share on revenue of $75.78 million. 
• Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $145.00 million. 
• Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is expected to report quarterly earnings at $1.47 per share on revenue of $14.62 billion. 
• Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) is estimated to report earnings for its fourth quarter. 
• Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $42.70 million. 
• Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $980.87 million. 
• Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) is expected to report quarterly earnings at $4.01 per share on revenue of $62.61 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCS

ACDC

AOUT

APEI

ARCT

ASLE

ASUR

AVGO

AVIR

BBAI

BTSG

BURL

CANG

CBRL

CHMI

COOK

COST

CRMT

CTMX

DLNG

DOMO

DSGR

DXPE

ELUT

EVGN

FDUS

FNKO

GENK

GEVO

GHLD

GRNT

GWRE

HDSN

HIPO

KVHI

LOCO

LODE

LOMA

LXRX

MCHX

MLNK

MNMD

MODV

MOLN

NCMI

NDLS

PACK

PBPB

PHAT

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTH

PSNY

REAX

REFR

RELI

SAMG

SERV

SHIP

STVN

SUNS

SWBI

TRMD

VRME

WLDN

WLYB

XERS

XTNT

Earnings Scheduled For March 6, 2025

Delcath Systems Says Updated National Comprehensive Cancer Network Guidelines Now Include HEPZATO KIT As A Category 2A For Patients With Hepatic-Dominant Uveal Melanoma

Craig-Hallum analyst Chase Knickerbocker maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and raises the price target from $18 to $21.

Craig-Hallum Maintains Buy on Delcath Systems, Raises Price Target to $21

In the latest quarter, 4 analysts provided ratings for Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.75, with a high estimate of $22.00 and a low estimate of $21.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1736859655_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Delcath Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Delcath Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Delcath Systems compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Delcath Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Delcath Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DCTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delcath Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Delcath Systems's Background</h2>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Delcath Systems: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Delcath Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2480.65% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Delcath Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Delcath Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Delcath Systems's ROA stands out, surpassing industry averages. With an impressive ROA of 5.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.36, Delcath Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Delcath Systems's Future

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $22 price target.

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $22 Price Target

Comments

Delcath Systems

Delcath Systems (DCTH) Opzioni

Delcath Systems (NASDAQ:DCTH) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO